Clinical Trials

NCT Number: NCT05501548 Phase: PHASE2 Trial Summary: This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer pati – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center […]

NCT Number: NCT05633160 Phase: PHASE1|PHASE2 Trial Summary: The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Clarity Pharmaceuticals Ltd Acronym: COMBAT

NCT Number: NCT05613894 Phase: PHASE1 Trial Summary: This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC. The primary hypothesis is that cabozantinib with 177Lu-PSMA will be saf – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah Acronym: CaboLu

NCT Number: NCT05647564 Phase: NA Trial Summary: This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of ima – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Wisconsin, Madison Acronym:

NCT Number: NCT05478239 Phase: PHASE2 Trial Summary: Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical pr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Zin W Myint Acronym:

NCT Number: NCT05616650 Phase: PHASE2 Trial Summary: Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now see – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT05445609 Phase: PHASE2 Trial Summary: This phase II trial tests whether vidutolimod with nivolumab works to destroy tumor cells in patients with castration resistant prostate cancer that has spread to other places in the body (metastatic) – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Emory University Acronym:

NCT Number: NCT05864196 Phase: PHASE1 Trial Summary: Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NYU Langone Health Acronym:

NCT Number: NCT04808427 Phase: NA Trial Summary: Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods. Ob – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): National Cancer Institute (NCI) Acronym:

NCT Number: NCT05915442 Phase: PHASE2 Trial Summary: This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Catherine Spina Acronym: SBRT-AMICO